Shares of CME Group, Inc. (CME) have fallen 19.8% over the past three months, closing at $246.38, near its 52-week low of $244.56. This decline contrasts with a 9.7% drop in the broader industry. The stock’s decrease has been attributed to concerns over its premium valuation, competitive threats, and investor selling pressure, particularly following a recent leadership transition announcement.
Despite the downturn, the Zacks average price target for CME is $308.80 per share, indicating a potential upside of 22.3%. The company is projected to see a 9.6% increase in earnings per share (EPS) by 2026, alongside expected revenues of $7.05 billion, an 8.1% rise year-over-year. CME’s strong liquidity position includes $2.6 billion in cash against long-term debt of $3.4 billion.
However, CME faces risks from interest-rate volatility, currency fluctuations, and heightened competition in the trading space. The company anticipates adjusted operating expenses to reach approximately $1.695 billion in 2026, heightening concerns about future growth amidst rising costs.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
